Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named for the GLP-1 products, whose pages give the source only as a 503A pharmacy. The NAD+ page names Olympia as its 503B source with no city or state, and the terms refer only to affiliated and unaffiliated pharmacies. 1 more criterion also fails; see the table below.
At a glance
LumiMedsTelehealth service
6/8criteria passed
Price
Semaglutide as low as $89 a month, tirzepatide as low as $125
Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.
A Las Vegas patient management platform selling compounded semaglutide and tirzepatide plans and NAD+ injections on monthly and longer plans, with care from independent physicians under a named medical director. Care starts with a health assessment, and the pharmacy that fills its GLP-1 prescriptions is not named.
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSA licensed US provider reviews each intake and prescribes only if appropriate, and the home page names Dr. Teresa Walsh, M.D., board certified in obesity medicine, as medical director overseeing the clinical protocols.Source: LumiMeds' website; LumiMeds' GLP-1 plans product page; LumiMeds' terms of use page.
S2PASSThe home page and each product page put a health assessment first and a provider review second, and say the buyer is refunded in full if the provider decides treatment is not right. The membership terms say full refunds are issued in the event of a prescription denial.Source: LumiMeds' website; LumiMeds' GLP-1 plans product page; LumiMeds' memberterms page.
S3FAILNo filling pharmacy is named for the GLP-1 products, whose pages give the source only as a 503A pharmacy. The NAD+ page names Olympia as its 503B source with no city or state, and the terms refer only to affiliated and unaffiliated pharmacies.Source: LumiMeds' GLP-1 plans product page; LumiMeds' GLP-1 GIP plans product page; LumiMeds' NAD+ plans product page; LumiMeds' terms of use page.
S4PASSEach product page states that compounded drugs are not FDA-approved as a finished product, and the footer of every page says compounded medications are not FDA-approved, have not been evaluated by the FDA and are not brand-name or generic drugs.Source: LumiMeds' GLP-1 plans product page; LumiMeds' GLP-1 GIP plans product page; LumiMeds' website.
S5FAILNo certificate of analysis or lot document is published. The semaglutide answers say the medication is prepared at a cGMP-compliant pharmacy, with no document behind the claim.Source: LumiMeds' GLP-1 plans product page; LumiMeds' NAD+ plans product page.
S6PASSLuminate Ventures LLC, doing business as Lumimeds, at 1810 E Sahara Ave, Suite 215, Las Vegas, NV 89104, printed in the contact blocks of the terms of use and the membership terms. The membership terms name Nevada law.Source: LumiMeds' terms of use page; LumiMeds' memberterms page.
S7PASSCompounded semaglutide as low as $89 a month and compounded tirzepatide as low as $125 a month, with provider review, medication and shipping included, on monthly, 3, 6 and 12-month plans whose separate prices are not printed. NAD+ as low as $119 a month on monthly or 3-month plans, with 20% off advertised on its card.Source: LumiMeds' products page; LumiMeds' GLP-1 plans product page; LumiMeds' GLP-1 GIP plans product page; LumiMeds' NAD+ plans product page.
S8PASSFDA warning letter 716510, September 2025, names Lumimeds in Las Vegas, Nevada, at the website this seller trades from, and alleges that claims of the same active ingredient as brand-name medications were false or misleading for its compounded semaglutide and tirzepatide. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 716510.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, NAD+ injections.
FDA warning letter 716510, issued September 2025, to LumimedsClaims that compounded tirzepatide and semaglutide have the same active ingredient as the brand name medications, and that the ingredient was FDA-approved in 2017 and for weight loss in 2021, imply the products are the same as FDA-approved drugs, which the letter calls false or misleading.
A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.